Brief: Tectonic Therapeutic Announces Us Ind Clearance For Lead Program, Tx45
30/07/2024 21:20
July 30 (Reuters) - Tectonic Therapeutic Inc TECX.O :
* TECTONIC THERAPEUTIC ANNOUNCES US IND CLEARANCE FOR LEAD
PROGRAM, TX45
* EXPECTS TO INITIATE GLOBAL PHASE 2 CLINICAL TRIAL OF TX45
IN
PH-HFPEF IN Q3 OF 2024, WITH TOPLINE RESULTS ANTICIPATED IN 2026
Source text for Eikon: ID:nGNX6nw9nR
Further company coverage: TECX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tectonic Therapeutic
See all newsTectonic Therapeutic Inc reports results for the quarter ended June 30 - Earnings Summary
Tectonic Therapeutic Q2 net loss widens on higher costs
Tectonic Therapeutic Inc expected to post a loss of $1.35 a share - Earnings Preview
Brief: Tectonic Therapeutic Completes Enrollment In Tx45 Apex Phase 2 Clinical Trial In Ph-Hfpef Patients
Tectonic Therapeutic Q1 net loss widens on higher R&D costs